DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 76 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Sanofi India Limited — Updates

NSE 1 hr ago·28 Sept 2026, 8:56 am

Sanofi India

Sanofi India has informed stock exchanges that it has made a regulatory disclosure under SEBI's Prohibition of Insider Trading (PIT) regulations. This specific disclosure typically relates to the transfer of shares by a promoter, director, or designated person. The company has not provided any further details regarding the transaction at this time.

This disclosure is a standard procedural requirement under Indian securities laws. It ensures transparency and helps prevent insider trading by informing the market about potential changes in shareholding patterns. For investors, this update confirms that the company is in compliance with regulatory norms and that no material information has been released beyond this filing.

Investors should wait for the company's official press release or subsequent announcements to understand the context of this disclosure. Until then, the market will view this as a routine regulatory filing with no immediate impact on the stock's fundamentals.